Literature DB >> 22903204

Overexpression of metadherin/MTDH is associated with an aggressive phenotype and a poor prognosis in invasive breast cancer.

Eriko Tokunaga1, Yuichiro Nakashima, Nami Yamashita, Yuichi Hisamatsu, Satoko Okada, Sayuri Akiyoshi, Shinichi Aishima, Hiroyuki Kitao, Masaru Morita, Yoshihiko Maehara.   

Abstract

BACKGROUND: Metadherin (MTDH) plays functional roles in the tumorigenesis and tumor progression of various cancers. This study investigated the associations between MTDH and the clinicopathological features in primary breast carcinomas to clarify the role of MTDH in the phenotypes and prognosis of breast cancer.
METHODS: A total of 195 primary invasive breast cancer samples were evaluated. The MTDH DNA copy number and MTDH mRNA expression were analyzed by quantitative genomic polymerase chain reaction (PCR) and quantitative reverse transcriptase PCR. MTDH protein expression was analyzed by immunohistochemistry.
RESULTS: A positive correlation was found between the expression of MTDH protein and mRNA expression and the MTDH DNA copy number. MTDH overexpression was significantly associated with a high nuclear grade, negative estrogen receptor (ER) and progesterone receptor (PR) expression, high Ki67 index, poor disease-free survival (P = 0.0001), poor distant metastasis-free survival (P = 0.009), and poor overall survival (P = 0.0101). MTDH overexpression showed a particularly negative impact on the prognosis in node-negative patients. A multivariate analysis showed MTDH overexpression to be independently associated with a poor disease-free survival rate [HR 3.45, 95 % confidence interval (CI) 1.69-6.84, P = 0.0010] and a poor distant metastasis-free survival rate (HR 2.39, 95 % CI 1.08-5.01, P = 0.0319).
CONCLUSION: MTDH overexpression contributes to an aggressive phenotype, thus leading to a poor prognosis for primary invasive breast cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22903204     DOI: 10.1007/s12282-012-0398-2

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  23 in total

Review 1.  AEG-1/MTDH/LYRIC, the beginning: initial cloning, structure, expression profile, and regulation of expression.

Authors:  Seok-Geun Lee; Dong-Chul Kang; Rob DeSalle; Devanand Sarkar; Paul B Fisher
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

Review 2.  Drug resistance mediated by AEG-1/MTDH/LYRIC.

Authors:  Xiangbing Meng; Kristina W Thiel; Kimberly K Leslie
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

3.  AEG-1/MTDH/LYRIC: signaling pathways, downstream genes, interacting proteins, and regulation of tumor angiogenesis.

Authors:  Luni Emdad; Swadesh K Das; Santanu Dasgupta; Bin Hu; Devanand Sarkar; Paul B Fisher
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

4.  Metadherin in prostate, bladder, and kidney cancer: A systematic review.

Authors:  Zhao Wang; Yong-Bao Wei; Yun-Liang Gao; Bin Yan; Jin-Rui Yang; Qiong Guo
Journal:  Mol Clin Oncol       Date:  2014-08-18

Review 5.  The role of MTDH/AEG-1 in the progression of cancer.

Authors:  Xue Shi; Xin Wang
Journal:  Int J Clin Exp Med       Date:  2015-04-15

6.  The expressions of metadherin and LEF-1 in mucosa-associated lymphoid tissue lymphoma of ocular adnexal.

Authors:  Dan Qi; Hong Lin; Yan Gao; Jing Lin; Li-Ting Hu; Gui-Qiu Zhao
Journal:  Int J Ophthalmol       Date:  2017-05-18       Impact factor: 1.779

7.  Metadherin contributes to the pathogenesis of chronic lymphocytic leukemia partially through Wnt/β-catenin pathway.

Authors:  Pei-Pei Li; Li-Li Feng; Na Chen; Xue-Ling Ge; Xiao Lv; Kang Lu; Mei Ding; Dai Yuan; Xin Wang
Journal:  Med Oncol       Date:  2015-01-10       Impact factor: 3.064

Review 8.  Astrocyte elevated gene-1 (AEG-1) and the A(E)Ging HIV/AIDS-HAND.

Authors:  Neha Vartak-Sharma; Shruthi Nooka; Anuja Ghorpade
Journal:  Prog Neurobiol       Date:  2016-04-14       Impact factor: 11.685

9.  A novel metadherinΔ7 splice variant enhances triple negative breast cancer aggressiveness by modulating mitochondrial function via NFĸB-SIRT3 axis.

Authors:  Praveen Kumar Neeli; Paradesi Naidu Gollavilli; Sreevidya Mallappa; Sai Gayathri Hari; Srigiridhar Kotamraju
Journal:  Oncogene       Date:  2019-12-05       Impact factor: 9.867

10.  Progress of cancer research on astrocyte elevated gene-1/Metadherin (Review).

Authors:  Yong Huang; LE-Ping Li
Journal:  Oncol Lett       Date:  2014-06-05       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.